ArticleAnnals of surgical oncology2026
circ_PPAPDC1A is Associated with Brain Metastasis of Non-Small-Cell Lung Cancer via the miR-30a-3p/SPOCK1 Pathway.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundBrain metastasis (BM) is a leading cause of mortality in non-small-cell lung cancer (NSCLC). The abnormal expression and regulation of circular RNA (circRNA) is involved in the pathogenesis of various tumors. However, the involvement of circRNAs in BM of NSCLC remains to be elucidated.
methodsIn this study, we established an in vitro blood-brain barrier (BBB) model using BM NSCLC cell lines H2030-BrM3 and PC9-BrM3. We investigated the impact of circ_phosphatidic acid phosphatase type 2 domain containing 1A (PPAPDC1A) on BM of NSCLC in vitro. The interaction between circ_PPAPDC1A and sparc/osteonectin, cwcv and kazal-like domain proteoglycan 1 (SPOCK1) axes was validated through RNA pull-down and dual-luciferase reporter assays.
resultsOur findings revealed that circ_PPAPDC1A was significantly upregulated in NSCLC with BM (P=0.018). Moreover, exosomes of circ_PPAPDC1A exhibited high diagnostic accuracy for BM, with an area under the curve of 0.83 (P = 0.003), and were closely associated with shorter progression-free survival (6.15 vs. 9.25 months; P = 0.019) and BM-free survival (5.41 vs. 7.75 months; P = 0.18). Functionally, circ_PPAPDC1A overexpression was associated with enhanced in vitro features related to BM, whereas silencing circ_PPAPDC1A showed opposite trends (P < 0.05). Mechanistically, circ_PPAPDC1A functions as efficient microRNA (miR-30a-3p) sponges, thereby activating its downstream functional target, SPOCK1 (P < 0.05).
conclusionsFor the first time, we identified that circ_PPAPDC1A is significantly upregulated and associated with oncogenic effects in NSCLC with BM, potentially via sponging the miR-30a-3p-SPOCK1 pathway. circ_PPAPDC1A shows potential as a diagnostic biomarker and therapeutic target candidate for patients with NSCLC with BM, pending further validation.
Indexed as
Identifiers
41136871What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.